key: cord-0257877-5lqjmqu5 authors: V, J. K.; Sowpati, D. T.; Munigela, A.; Banu, S.; Siva, A. B.; Sasikala, M.; Nutalapati, C.; Kulkarni, A.; Mukherjee, P.; Zaveri, L.; CCMB COVID-19 Team,; AIG Hospitals COVID-19 Vaccine study Team,; Tallapaka, K. B.; D, N. R. title: Clinical outcomes in vaccinated individuals hospitalized with Delta variant of SARS-CoV-2 date: 2021-07-16 journal: nan DOI: 10.1101/2021.07.13.21260417 sha: c609025a2f5c357ae3858bcf5e238f9866619ea2 doc_id: 257877 cord_uid: 5lqjmqu5 Emerging variants of SARS-CoV-2 with increased transmissibility or immune escape have been causing large outbreaks of COVID-19 infections across the world. As most of the vaccines currently in use have been derived from viral strains circulating in the early part of the pandemic, it becomes imperative to constantly assess the efficacy of these vaccines against emerging variants. In this hospital-based cohort study, we analysed clinical profiles and outcomes of 1161 COVID-19 hospitalized patients (vaccinated with COVISHIELD (ChAdOx1) or COVAXIN (BBV-152), n = 495 and unvaccinated n = 666) in Hyderabad, India between April 24th and May 31st 2021. Viral genome sequencing revealed that >90% of patients in both groups were harbouring the Delta variant (Pango lineage B.1.617.2) of SARS-CoV-2. Vaccinated individuals showed higher neutralizing antibodies (545+-1256 AU/ml Vs 51.1+-296 AU/ml; p<0.001) and significantly decreased Ferritin (392.26+-448.4 ng/mL Vs 544.82+-641.41 ng/mL; p<0.001) and LDH (559.45+-324.05 U/L Vs 644.99+- 294.03 U/L; p<0.001), when compared to the unvaccinated group. Severity of the disease (3.2% Vs 7.2%; p=0.0039) and requirement of ventilatory support (2.8% Vs 5.9%; p=0.0154) were significantly low in the vaccinated group despite the fact that these individuals had significantly higher age and risk factors. The rate of mortality was about 50% lower (2/132=1.51%) in the completely vaccinated breakthrough infections although mortality in individuals who had received a single dose was similar to the unvaccinated group (9/269=3.35% vs 23/666= 3.45%). Our results demonstrate that both COVISHIELD and COVAXIN are effective in preventing disease severity and mortality against the Delta variant in completely vaccinated hospitalized patients. New variants of SARS-CoV-2 continue to emerge as the virus spreads among hosts and mutates. Some of the variants, termed variants of concern, show increased transmissibility or capacity to bypass existing immunity, and are associated with large outbreaks of COVID-19 infections across the world (1, 2) . The Delta variant or the lineage B.1.617.2 of SARS-CoV-2, first sampled in late 2020 in India, is a highly transmissible variant and has been associated with the large second wave of COVID-19 in India (3) . The variant has now spread to more than 92 countries (4) and has become the largest circulating viral strain in the world. From the experience so far, vaccination has been the most effective public health intervention in curtailing the spread of the pandemic. As most of the vaccines currently in use have been derived from viral strains circulating in the early part of the pandemic, it becomes imperative to constantly assess their efficacy against emerging variants and make changes to the vaccine composition, as and when necessary (5) . In vitro studies so far have revealed decreased neutralizing efficacy of the Pfizer-BioNTech vaccine (BNT162b2) and the Oxford-AstraZeneca vaccine (ChAdOx1) against the Delta variant (6) . In the current study, we assessed the clinical outcomes of A total of 1161 SARS-CoV-2 infected patients admitted into AIG Hospitals (a tertiary care referral hospital in Hyderabad, India) during the above mentioned time period, All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure 1A ]. This was comparable to the prevalence of the variant in the community during this period [ Figure S1 ]. Hence, it may be safe to assume that the proportions will hold true in the remaining samples where viral genome sequencing could not be done. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2021. ; https://doi.org/10.1101/2021.07.13.21260417 doi: medRxiv preprint individuals who received both the doses when compared with those who received a single dose [ Figure 1C , Figure S2 ]. Individuals having higher antibody titres in the unvaccinated group were found to have IgM antibodies suggesting that these were acute infections and not reinfections or breakthrough infections. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2021. ; https://doi.org/10.1101/2021.07.13.21260417 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2021. ; https://doi.org/10.1101/2021.07.13.21260417 doi: medRxiv preprint Severity of the disease (Severity/ICU requirement at admission) was significantly low in the vaccinated group when compared to the unvaccinated (3.18% Vs 7.06%; p=0.0039). Requirement of ventilatory support was low as well (2.8% Vs 5.7%; p=0.0156). No significant differences were seen in the incidence of acute kidney injury (AKI), requirement for renal replacement therapy (RRT) or thrombotic complications between both the groups [ Table 1 ]. Mortality was 50% lower (2/132=1.51%) in fully Within the vaccinated group, neutralizing antibody response and total leukocyte counts were significantly higher, and serum Ferritin levels were significantly lower in those who received COVISHIELD (both doses) than those who received COVAXIN (both doses) [ Table 2 ]. However, no significant difference was seen in severity/mortality between both the groups. The clinical profiles of both the vaccinated groups were comparable ( Table 2 ). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2021. ; https://doi.org/10.1101/2021.07.13.21260417 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Whole genome sequencing of SARS-CoV-2 Viral RNA from COVID-19 infected patients was sequenced using COVIDSeq (Illumina, USA) according to the manufacturer's protocol. Briefly, first strand cDNA was synthesized using random hexamers and reverse transcriptase. Viral first strand cDNA was amplified using two primer pools. Post amplification, the two pools were combined, tagmented, and purified. An amplification step was performed to add a 10 base index and sequencing adapter, and the samples were purified using All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2021. ; https://doi.org/10.1101/2021.07.13.21260417 doi: medRxiv preprint paramagnetic beads to ensure selection of optimal sized fragments required for sequencing. Purified samples were quantified, normalized and sequenced on a NovaSeq 6000 (Illumina, USA) to obtain 100bp paired-end reads. Base calling was performed on raw image data using bcl2fastq v2.20.0.422 (Illumina). FASTQC v0.11.9 (7) was used to assess the quality of reads. Trimmomatic was used to trim poor quality bases and adapter sequences (8) . Mapping of reads to the indexed reference genome NC_045512.2 was done using HISAT2 v2.1.0 (9). Consensus sequences were generated using bcftools from the BAM file post alignment. Coverage across the genome was calculated using samtools depth. PANGO v3.0.5 (3) was used to assign lineages to the consensus sequences. Mutations in the sequences were identified using Nextclade v1.1.0 (10). Data was analyzed using the R statistical environment. Categorical data including gender, comorbidities, outcomes of COVID-19 is expressed as numbers (%). Continuous variables including age, biochemical variables (hemogram, LFT and serum creatinine), inflammatory variables (Ferritin, LDH, CRP, and D-dimer) are expressed as means (standard deviation [SD]). Categorical data was compared using Fisher's exact test while continuous data was compared using Student's t-test. All statistical tests with p<0.05 were considered significant. Data was visualized using the ggplot2 package in R. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2021. ; https://doi.org/10.1101/2021.07.13.21260417 doi: medRxiv preprint Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at SARS-CoV-2 variants, spike mutations and immune escape Genomic characterization and Epidemiology of an emerging SARS-CoV-2 variant in Delhi Assignment of Epidemiological Lineages in an Emerging Pandemic Using the Pangolin Tool. Virus Evolution SARS-CoV-2 vaccines and the growing threat of viral variants Reduced neutralisation of the Delta (B. 1.617. 2) SARS-CoV-2 variant of concern following vaccination. medRxiv Babraham Bioinformatics -FastQC A Quality Control tool for High Throughput Sequence Data Trimmomatic: a flexible trimmer for Illumina sequence data Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype Nextstrain: real-time tracking of pathogen evolution (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted July 16, 2021.